8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex

8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex

Postoperative residual neuromuscular blockade (PORNB) is a prevalent and preventable cause of post-anaesthesia pulmonary complications, upper airway collapse, and hypoxemia. Eliminating residual paralysis requires an understanding of peripheral nerve stimulation patterns, muscle sensitivity differences, objective quantitative monitors, and reversal pharmacology.

---

1. Principles of Neuromuscular Stimulation Modalities

Neuromuscular monitors apply supramaximal electrical impulses (typically 40 to 70 mA, monophasic square-wave duration 0.2 ms) to a peripheral motor nerve, depolarizing all axonal fibers simultaneously.

                             [ STIMULATION PATTERNS ]
                                        |
        +-------------------------------+-------------------------------+
        |                               |                               |
   [ TRAIN-OF-FOUR (TOF) ]     [ DOUBLE BURST (DBS) ]         [ POST-TETANIC COUNT (PTC) ]
   - 4 pulses at 2 Hz (0.5 s)  - Two 50 Hz bursts separated   - 50 Hz tetanus for 5 s
   - TOF Ratio = $T_4 / T_1$     by 750 ms ($\text{DBS}_{3,3}$) - 3-second pause
   - Detects fade down to 0.4  - Tactile fade detected to 0.6 - 1 Hz single twitches (1-15)
   - Normal recovery $\ge 0.90$ - Tactile improvement over TOF - Quantifies DEEP block (TOF = 0)

Train-of-Four (TOF) Stimulation

TOF delivers four supramaximal pulses at a frequency of 2 Hz (one impulse every 0.5 seconds for 2 seconds). It is repeated at intervals no shorter than 12 to 15 seconds to prevent receptor fatigue.

• TOF Ratio ($TOFR$): The ratio of the amplitude of the fourth twitch to the first twitch ($T_4/T_1$). In unblocked muscle, the ratio is 1.0 (100%).
• Fade Mechanism: In non-depolarizing blockade, competitive antagonism of presynaptic nicotinic receptors blocks the positive feedback mechanism normally mediated by acetylcholine. Consequently, the readily releasable vesicular acetylcholine pool is depleted during rapid repetitive stimulation, producing progressive decline in twitch height ($T_4 < T_3 < T_2 < T_1$).

Receptor Occupancy and Clinical Twitch Correlation

During onset and spontaneous offset of a non-depolarizing block, twitches disappear and reappear in a predictable sequence based on receptor occupancy at the motor endplate:

• $T_4$ disappears: Correlates with approximately 75% receptor occupancy.
• $T_3$ disappears (2 twitches present): Correlates with approximately 80% receptor occupancy.
• $T_2$ disappears (1 twitch present): Correlates with approximately 85% to 90% receptor occupancy.
• $T_1$ disappears (0 twitches present): Correlates with $>90-95\%$ receptor occupancy (profound/deep block).
• Full recovery: All 4 twitches equal; receptor occupancy must fall below 70% for $TOFR$ to approach 0.90.

Double Burst Stimulation (DBS)

DBS consists of two short bursts of 50 Hz tetanic stimulation separated by a 750 ms interval. The most common configuration is $\text{DBS}_{3,3}$ (three impulses of 0.2 ms duration at 50 Hz, followed 750 ms later by three identical impulses). By compressing the stimuli into two distinct contractions, DBS amplifies the tactile and visual perception of muscle fade, enabling clinicians to palpate fade up to a TOF ratio of 0.60, whereas standard TOF fade is tactilely undetectable above a ratio of 0.40.

Tetanic Stimulation and Post-Tetanic Count (PTC)

• Tetanic Stimulation: High-frequency stimulation (50 Hz or 100 Hz for 5 seconds). In non-depolarizing block, tetanus demonstrates rapid fade. Following cessation of the tetanic train, massive presynaptic $Ca^{2+}$ influx triggers mobilization of reserve acetylcholine vesicles, producing transient post-tetanic potentiation.
• Post-Tetanic Count (PTC): Designed specifically to monitor deep neuromuscular blockade when the TOF count is zero ($T_1-T_4$ absent):
  1. A 50 Hz tetanic stimulus is delivered for 5 seconds.
  2. A 3-second pause follows to allow post-tetanic mobilization of acetylcholine.
  3. Single-twitch stimulation at 1 Hz is applied for 15 to 20 seconds.
  4. The number of twitches elicited is counted (the "Post-Tetanic Count").
• Clinical Interpretation:
  • $\text{PTC} = 0$: Intense blockade (no response; minutes before first twitch reappears).
  • $\text{PTC} = 1 - 2$: Deep blockade; indicates that spontaneous return of $T_1$ will take approximately 10 to 20 minutes (for rocuronium/vecuronium).
  • $\text{PTC} \ge 8 - 10$: Transitioning to moderate blockade; reappearance of $T_1$ is imminent.

---

2. Quantitative vs Qualitative Monitoring and Recovery Criteria

Residual neuromuscular blockade cannot be diagnosed clinically. Subjective qualitative assessment (visual inspection or tactile palpation of twitches) is dangerously inaccurate. Controlled trials demonstrate that experienced clinicians fail to tactilely detect fade when the true TOF ratio is between 0.40 and 0.90.

Traditional clinical tests of recovery—such as a 5-second head lift, sustained tongue protrusion, firm hand grip, or adequate negative inspiratory force—can be successfully performed by patients with TOF ratios as low as 0.50 to 0.60, despite persistent profound impairment of pharyngeal and respiratory protective reflexes.

Quantitative Technologies

Objective quantitative monitors measure the true mechanical or electrical response and compute an exact numerical TOF ratio ($T_4/T_1$):

1. Acceleromyography (AMG): Measures the acceleration of the thumb (adductor pollicis) using a piezoelectric transducer following ulnar nerve stimulation, applying Newton's Second Law ($F = m \cdot a$). Baseline uncalibrated values often exceed 1.0 (reverse fade), requiring baseline normalization.
2. Electromyography (EMG): Measures the compound muscle action potential (CMAP) across the muscle belly. EMG represents the gold standard of monitoring: it measures true electrical depolarization, requires no physical movement of the digit, and functions reliably when the patient's arm is tucked.
3. Kinemyography (KMG): Measures the mechanical deflection and bending of a piezoelectric sensor positioned in the groove between thumb and index finger.

The Definition of Adequate Recovery: TOF Ratio $\ge 0.90$

Complete and safe recovery from neuromuscular blockade is defined as a quantitative Train-of-Four ratio $\ge 0.90$ (90%) measured at the adductor pollicis.

                             [ TOF RATIO SPECTRUM ]

  0.0 ---------------- 0.40 ---------------- 0.70 ---------------- 0.90 -------- 1.0
   |                    |                    |                    |
   Profound/Deep        Tactile Fade Lost    5-sec Head Lift      SAFE EXTUBATION
   Blockade             (Subjective TOF      Can Be Performed;    Full upper airway
   (PTC Monitoring)     Deceptive)           Severe Aspiration    stability restored
                                             Risk Persists

Consequences of Residual Neuromuscular Blockade (TOFR < 0.90):

• Upper Airway Vulnerability: Selective weakness of the pharyngeal constrictors and genioglossus, causing dynamic upper airway collapse and obstruction.
• Blunted Hypoxic Ventilatory Response: Impairment of carotid body chemoreceptor sensitivity (mediated by nicotinic receptor blockade), attenuating hyperventilation in response to arterial hypoxemia.
• Pharyngeal Dyscoordination: Incomplete laryngeal elevation and impaired upper esophageal sphincter relaxation, precipitating silent micro-aspiration of gastric secretions.
• Increased Morbidity: Higher incidence of postoperative atelectasis, pneumonia, and emergency reintubation in the post-anaesthesia care unit (PACU).

---

3. Differential Sensitivity of Muscle Groups

Skeletal muscle groups exhibit distinct pharmacodynamic sensitivities to neuromuscular blocking agents based on local capillary density, blood flow, acetylcholine receptor density, and muscle fiber composition.

                                [ SENSITIVITY GRADIENT ]

  RESISTANT (Fast Onset, Early Recovery)       SENSITIVE (Slow Onset, Delayed Recovery)
  ======================================       =======================================
  Diaphragm                                    Genioglossus & Pharyngeal Dilators
  Laryngeal Adductors                          Adductor Pollicis (Thumb)
  Masseter & Corrugator Supercilii             Orbicularis Oculi

Diaphragm and Laryngeal Muscles vs Adductor Pollicis

• Diaphragm and Vocal Cords: Receive high blood flow and have high density of motor endplates. They are relatively resistant to neuromuscular blockade. They require 1.5 to 2 times the dose of NMBD to achieve the same degree of paralysis as peripheral muscles. Their onset of blockade is faster, but they recover substantially earlier than the peripheral musculature.
• Adductor Pollicis (Thumb): Innervated by the ulnar nerve. Highly sensitive to NMBDs. Onset is slower, but recovery is significantly delayed compared to the diaphragm.

Facial Muscles: Corrugator Supercilii vs Orbicularis Oculi

When the facial nerve (CN VII) is stimulated:

• Corrugator Supercilii (Eyebrow Furrowing): Its onset and recovery kinetics closely mirror the laryngeal adductors and diaphragm. Monitoring at the corrugator supercilii provides the best predictor of optimal vocal cord relaxation for endotracheal intubation.
• Orbicularis Oculi (Eye Closure): Intermediate sensitivity.

The Essential Clinical Rule: Monitoring facial muscles at the eye dangerously overestimates recovery! The diaphragm and corrugator supercilii can demonstrate full recovery (4 twitches, no fade) while the adductor pollicis—and critically, the pharyngeal and upper-airway dilator muscles—remain significantly weak. Extubation must never be based on facial nerve monitoring; safe recovery must ALWAYS be confirmed by quantitative monitoring at the adductor pollicis.

---

4. Anticholinesterase Reversal: Neostigmine

Neostigmine is a synthetic quaternary ammonium compound that inhibits acetylcholinesterase, prolonging the lifespan of acetylcholine in the synaptic cleft.

Mechanism of Action and Ceiling Effect

Neostigmine forms a carbamyl ester complex with the esteratic site of acetylcholinesterase (AChE). This carbamylation inhibits the enzyme for 1 to 2 hours, preventing the enzymatic hydrolysis of acetylcholine. The resulting accumulation of endogenous ACh competes with and displaces non-depolarizing blockers from the postjunctional $nAChR$.

The Ceiling Effect: Neostigmine exhibits a rigid pharmacological ceiling effect. Once acetylcholinesterase is 100% inhibited, administering additional neostigmine cannot produce any further increase in synaptic acetylcholine. At excessive doses, neostigmine directly causes depolarizing neuromuscular block and receptor desensitization. Consequently, neostigmine cannot reverse deep neuromuscular blockade (PTC 1-2, TOF = 0). The 2023 ESAIC and ASA guidelines recommend sugammadex for deep, moderate and shallow aminosteroid block; neostigmine (maximum about $40 - 50\text{ }\mu\text{g/kg}$) is a reasonable alternative only for minimal block (four twitches with a quantitative TOF ratio of about 0.4 to below 0.9), with recovery confirmed by quantitative monitoring.

Muscarinic Adverse Effects and Antimuscarinic Co-Administration

Inhibiting acetylcholinesterase increases acetylcholine at all cholinergic synapses throughout the body, including parasympathetic muscarinic ($M_2, M_3$) receptors:

• Cardiac ($M_2$): Severe sinus bradycardia, junctional escape rhythms, atrioventricular block, and asystolic arrest.
• Respiratory ($M_3$): Bronchoconstriction and copious tracheobronchial secretions.
• Gastrointestinal ($M_3$): Increased peristalsis, abdominal cramping, and increased salivation.

Neostigmine must always be paired with an antimuscarinic agent:

• Glycopyrrolate: A synthetic quaternary amine that does not cross the blood-brain barrier. Its intermediate onset (~2 to 3 minutes) perfectly matches the onset profile of neostigmine (dosed at 10 to 20 $\mu\text{g}$ glycopyrrolate per 50 $\mu\text{g}$ neostigmine; typically 0.5 mg glycopyrrolate per 2.5 mg neostigmine IV).
• Atropine: A tertiary amine that rapidly crosses the blood-brain barrier. It has a faster onset than neostigmine, predisposing to initial transient tachycardia and central anticholinergic agitation; historically paired with edrophonium.

---

5. Selective Relaxant Binding Agents: Sugammadex

Sugammadex represents a paradigm shift in neuromuscular reversal, functioning as a Selective Relaxant Binding Agent (SRBA) rather than an enzymatic inhibitor.

                               [ SUGAMMADEX STRUCTURE ]

                                  O       O       O
                                 / \     / \     / \
                                |   |---|   |---|   |
                                 \ /     \ /     \ /
                             [ Hydrophobic Central Cavity ]
                                      (Diameter ~7.5-8.3 Å)
                                 / \     / \     / \
                                |   |---|   |---|   |
                                 \ /     \ /     \ /
                                  S       S       S
                                  |       |       |
                              (CH_2)_2 (CH_2)_2 (CH_2)_2
                                  |       |       |
                                 COO^-   COO^-   COO^-
                             [ 8 Carboxyl Thioether Side Chains ]

Chemical Architecture and Binding Mechanism

Sugammadex is a modified $\gamma$-cyclodextrin consisting of 8 glucopyranose units arranged in a hollow, doughnut-shaped torus:

• Hydrophobic Cavity: The interior cavity has a lipophilic diameter (~7.5 to 8.3 Å) precisely engineered to encapsulate the steroidal four-ring nucleus of aminosteroid muscle relaxants.
• Negatively Charged Rim: The primary rim is modified with eight carboxyl thioether extensions, providing negative electrostatic charges that lock onto the positively charged quaternary nitrogens of the target relaxant.
• Affinity Spectrum: Binds with extraordinarily high affinity: Rocuronium > Vecuronium >> Pancuronium. Sugammadex has zero affinity for benzylisoquinolinium agents (atracurium, cisatracurium) or depolarizing blockers (suxamethonium).

Pharmacokinetics of Reversal

Sugammadex encapsulates rocuronium in a 1:1 molecular complex held together by van der Waals forces and hydrophobic interactions. Encapsulation of free rocuronium molecules in the plasma drops free intravascular concentration to near zero. This generates a steep concentration gradient that rapidly draws rocuronium molecules away from the neuromuscular junction back into the circulation, where they are irreversibly encapsulated. The biologically inactive sugammadex-rocuronium complex is excreted unchanged in urine by glomerular filtration.

Dosing Guidelines (Calculated on ACTUAL Total Body Weight)

Sugammadex dosing is strictly based on actual total body weight, NOT ideal body weight:

1. 2 mg/kg: For routine reversal of moderate blockade upon the reappearance of the second twitch ($T_2$) on Train-of-Four. Achieves $TOFR \ge 0.90$ within 2 minutes.
2. 4 mg/kg: For reversal of deep blockade when there is zero TOF response ($T_1 = 0$), but a Post-Tetanic Count of PTC 1 to 2 is confirmed. Achieves $TOFR \ge 0.90$ within 3 minutes.
3. 16 mg/kg: For immediate rescue reversal of profound blockade (e.g., in a "Cannot Intubate, Cannot Oxygenate" [CICO] emergency), administered approximately 3 minutes following a high induction dose of rocuronium ($1.2\text{ mg/kg}$). Reverses paralysis in ~1.5 to 3 minutes, faster than spontaneous recovery from suxamethonium.

Advantages over Neostigmine

• Reverses any depth of blockade (including deep and profound block where neostigmine fails).
• Eliminates autonomic muscarinic side effects; no antimuscarinic co-administration required.
• Significantly faster and more predictable recovery (<2-3 minutes vs 15-30 minutes for neostigmine).
• Eliminates the risk of anticholinesterase-induced muscle weakness.

Adverse Effects and Special Precautions

• Hypersensitivity and Anaphylaxis: Severe allergic reactions are rare; reported incidence varies widely between series (from roughly 1 in 2,500 to 1 in 35,000 administrations) and most appear IgE-mediated against the cyclodextrin.
• Transient Coagulation Abnormalities: Causes a transient, concentration-dependent prolongation of activated partial thromboplastin time (aPTT) and prothrombin time (PT/INR) of up to 25% lasting 30 to 60 minutes due to non-specific interaction with clotting factors; rarely causes clinical bleeding.
• Interaction with Hormonal Contraceptives: Sugammadex encapsulates circulating progesterone and synthetic progestins. Administering sugammadex (4 or 16 mg/kg) is equivalent to a missed daily dose of an oral contraceptive. Female patients of childbearing potential taking hormonal contraceptives must be explicitly counseled to utilize barrier contraception for 7 days post-operatively.
• Re-curarization and Renal Failure: In severe renal failure, clearance of the complex is delayed (complexes remain in plasma for up to 7 days), though free rocuronium is not released. If re-paralysis is urgently required after sugammadex, use a benzylisoquinolinium agent (cisatracurium) or follow the product information's waiting times and doses before re-administering an aminosteroid.